Contact this trialFirst, we need to learn more about you.
Proteasome Inhibitor
Isatuximab + VRd for Multiple Myeloma
Recruiting2 awardsPhase 3
Saint Petersburg, Florida
This trial is testing a new drug called isatuximab added to a standard treatment mix. It targets patients with newly diagnosed multiple myeloma who can't have a transplant. Isatuximab helps the immune system destroy cancer cells, while the other drugs kill cancer cells and reduce inflammation.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service